Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVI-PCI: Tirofiban vs Eptifibatide in PCI
NCT01522417Phase 2Completed
- Sponsor
- Medicure Inc.
- Start
- Apr 2012
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirofiban in myocardial infarction (MI), acute coronary syndrome (ACS) and unstable angina (3 arms), sponsored by Medicure Inc. Primary endpoint: Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding at 48 hours. Started Apr 2012; status: completed.
02
Drugs
tirofiban
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)unstable angina
Beyond the preview
Go deeper on NCT01522417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522417.